F. Nicoletti et al., SODIUM FUSIDATE IN GUILLAIN-BARRE-SYNDROME - A CASE-REPORT, Journal of Neurology, Neurosurgery and Psychiatry, 65(2), 1998, pp. 266-268
A patient with Guillain-Barre syndrome is reported on who responded fa
vourably to a short course treatment with the novel immunosuppressant
sodium fusidate (Fucidin), given at a daily dose of 1.5 g for one week
. Along with prompt and clear cut clinical improvement, treatment with
Fucidin was associated with a rapid decline in the blood concentratio
ns of inflammatory cytokines presumably implicated in the pathogenesis
of Guillain-Barre syndrome such as interleukin-2, interferon-gamma, a
nd tumor necrosis factor-a. The ex vivo production of these cytokines
was also markedly diminished compared with pretreatment values. Fucidi
n was well tolerated and no clinical or biochemical side effects were
seen.